Are PBMs Bad For Your Health?
Executive Summary
All these years, drug companies thought they were the big losers in the growing influence of pharmacy benefit managers (PBMs). They saw prices erode and profits decline as a result of aggressive rebate contracting and generic substitution. The winners were consumers and payers who got more efficient care and relief from the high drug prices.
You may also be interested in...
Medtronic Looks To Adaptive DBS To Advance Treatment Of Parkinson’s Disease
Medtronic is sponsoring a trial to evaluate its adaptive deep brain stimulation technology, a unique feature of the Percept PC device for treating Parkinson’s disease.
Merck & Co. Pivots To COVID-19 Treatments After Vaccines Disappoint
The company cited lackluster efficacy in its decision to discontinue development of V590 and V591. It will instead develop two drugs to treat COVID-19.
Regulatory Science Tools For Phantoms, Lab Methods Added To US FDA Catalog
The regulatory tools are for use in medical device development.
Need a specific report? 1000+ reports available
Buy Reports